| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794488 | Ophthalmology Retina | 2018 | 9 Pages |
Abstract
Consistent with general trends, the risk of key systemic SAEs was associated with age â¥85 years versus <85 years, but not with ranibizumab drug exposure. The difference between monthly versus PRN was inconclusive. There was no evidence of a dose effect. Interpretation of this retrospective analysis is limited because it was not prospectively powered for statistically definitive conclusions.
Keywords
CBVRBZATECerebrovascularnAMDAPTCSAEPRNTIAICD-9-CMPDTMyocardial infarctionAs Neededtransient ischemic attackneovascular age-related macular degenerationranibizumabarterial thromboembolic eventinternational classification of diseases, ninth revision, clinical modificationSerious adverse eventconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)cardiovascularodds ratioPVCEPAREuropean Public Assessment Report
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Pravin U. MD, Natasha PharmD, Steven PhD, Ronald A. PhD, Susanna M. PhD, RPh, Anne E. MD,